RAPT Therapeutics downgraded by Stifel with a new price target
$RAPT
Biotechnology: Pharmaceutical Preparations
Health Care
Stifel downgraded RAPT Therapeutics from Buy to Hold and set a new price target of $2.00 from $7.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/22/2025 | $6.00 | Buy | H.C. Wainwright |
| 12/26/2024 | $10.00 | Neutral → Buy | H.C. Wainwright |
| 11/13/2024 | $7.00 → $2.00 | Buy → Hold | Stifel |
| 11/11/2024 | $8.00 → $2.00 | Overweight → Neutral | Piper Sandler |
| 11/11/2024 | Neutral → Underweight | JP Morgan | |
| 5/14/2024 | Outperform → Peer Perform | Wolfe Research | |
| 5/10/2024 | Buy → Neutral | Guggenheim | |
| 5/10/2024 | $13.00 → $4.00 | Overweight → Equal Weight | Barclays |